oasis 1 oral semaglutide 50 mg obesity nejm 2023 results New in the September 18, 2025, issue of NEJM: Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA phase 3 trial) https://nej.md/4mpKXNp Orforglipron in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) https://nej.md/4ngEZ36 Oral Semaglutide at a Dose

In their study, this conjugation method gave an average DAR of 1.6, which was approximately the same number of sialic acid residues introduced per antibody

Catrina AI, et al

It is thought to be derived from neural crest, which is one of the embryologic tissue types

For athletes cutting down for competition or aesthetic goals, this 1015% enhancement translates to an additional 24 pounds of fat loss over a 12-week cutting phasemeaningful progress when every bit of body fat reduction matters

10.1038/s41420-024-02075-3 Cell Death Discov

It can affect whether youre focused, upbeat, and energetic or whether youre laid back, calm, or down